[
  {
    "ts": null,
    "headline": "Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming",
    "summary": "Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.",
    "url": "https://finnhub.io/api/news?id=58cf062de0b62a43333be43bed26cf79b7dd57ae23ace8f7c108b7af4f624e8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739205407,
      "headline": "Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming",
      "id": 132638958,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192903839/image_2192903839.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.",
      "url": "https://finnhub.io/api/news?id=58cf062de0b62a43333be43bed26cf79b7dd57ae23ace8f7c108b7af4f624e8e"
    }
  },
  {
    "ts": null,
    "headline": "A Historic Opportunity To Win Big With Dividend Stocks",
    "summary": "Discover why the current market provides a historic opportunity for dividend stocks and which names you should consider investing in. Read our list of dividend stock picks here.",
    "url": "https://finnhub.io/api/news?id=1b9ddb3548d22b7dbc65ec418cf2d6c014b2cb4c0f585649e38064244384b20e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739201299,
      "headline": "A Historic Opportunity To Win Big With Dividend Stocks",
      "id": 132635787,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why the current market provides a historic opportunity for dividend stocks and which names you should consider investing in. Read our list of dividend stock picks here.",
      "url": "https://finnhub.io/api/news?id=1b9ddb3548d22b7dbc65ec418cf2d6c014b2cb4c0f585649e38064244384b20e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Challenges Loom Amid Overvaluation",
    "summary": "Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth in FQ4.",
    "url": "https://finnhub.io/api/news?id=2053fa8465eb3edafc31554bb06eb6cb7617967a038d00a13a6bc606978ba4a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739180343,
      "headline": "Pfizer: Challenges Loom Amid Overvaluation",
      "id": 132631889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149808923/image_2149808923.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth in FQ4.",
      "url": "https://finnhub.io/api/news?id=2053fa8465eb3edafc31554bb06eb6cb7617967a038d00a13a6bc606978ba4a9"
    }
  }
]